Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 2
2007 2
2008 1
2010 2
2011 5
2012 7
2013 5
2014 5
2015 4
2016 5
2017 3
2018 3
2019 5
2020 6
2021 7
2022 7
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Molecular mimicry and cancer vaccine development.
Tagliamonte M, Cavalluzzo B, Mauriello A, Ragone C, Buonaguro FM, Tornesello ML, Buonaguro L. Tagliamonte M, et al. Mol Cancer. 2023 Apr 26;22(1):75. doi: 10.1186/s12943-023-01776-0. Mol Cancer. 2023. PMID: 37101139 Free PMC article. Review.
Microorganisms-derived antigens for preventive anti-cancer vaccines.
Buonaguro L, Cavalluzzo B, Mauriello A, Ragone C, Tornesello AL, Buonaguro FM, Tornesello ML, Tagliamonte M. Buonaguro L, et al. Among authors: tagliamonte m. Mol Aspects Med. 2023 Aug;92:101192. doi: 10.1016/j.mam.2023.101192. Epub 2023 Jun 7. Mol Aspects Med. 2023. PMID: 37295175 Review.
Peptide-based vaccine for cancer therapies.
Buonaguro L, Tagliamonte M. Buonaguro L, et al. Among authors: tagliamonte m. Front Immunol. 2023 Aug 16;14:1210044. doi: 10.3389/fimmu.2023.1210044. eCollection 2023. Front Immunol. 2023. PMID: 37654484 Free PMC article. Review.
Immunotherapy in hepatocellular carcinoma.
Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M. Buonaguro L, et al. Among authors: tagliamonte m. Ann Hepatol. 2019 Mar-Apr;18(2):291-297. doi: 10.1016/j.aohep.2019.04.003. Epub 2019 Apr 25. Ann Hepatol. 2019. PMID: 31047849 Free article. Review.
Selecting Target Antigens for Cancer Vaccine Development.
Buonaguro L, Tagliamonte M. Buonaguro L, et al. Among authors: tagliamonte m. Vaccines (Basel). 2020 Oct 17;8(4):615. doi: 10.3390/vaccines8040615. Vaccines (Basel). 2020. PMID: 33080888 Free PMC article. Review.
Combinatorial immunotherapy strategies for hepatocellular carcinoma.
Tagliamonte M, Petrizzo A, Tornesello ML, Ciliberto G, Buonaguro FM, Buonaguro L. Tagliamonte M, et al. Curr Opin Immunol. 2016 Apr;39:103-13. doi: 10.1016/j.coi.2016.01.005. Epub 2016 Feb 4. Curr Opin Immunol. 2016. PMID: 26851637 Review.
Virus-like Particles as Preventive and Therapeutic Cancer Vaccines.
Tornesello AL, Tagliamonte M, Buonaguro FM, Tornesello ML, Buonaguro L. Tornesello AL, et al. Among authors: tagliamonte m. Vaccines (Basel). 2022 Feb 2;10(2):227. doi: 10.3390/vaccines10020227. Vaccines (Basel). 2022. PMID: 35214685 Free PMC article. Review.
SARS-CoV-2 RNA polymerase as target for antiviral therapy.
Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM. Buonaguro L, et al. Among authors: tagliamonte m. J Transl Med. 2020 May 5;18(1):185. doi: 10.1186/s12967-020-02355-3. J Transl Med. 2020. PMID: 32370758 Free PMC article.
Antigen-specific vaccines for cancer treatment.
Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, Buonaguro L. Tagliamonte M, et al. Hum Vaccin Immunother. 2014;10(11):3332-46. doi: 10.4161/21645515.2014.973317. Hum Vaccin Immunother. 2014. PMID: 25483639 Free PMC article. Review.
73 results